Propanc Biopharma Demonstrates Significant Effects of Proenzyme Therapy on the Tumor Microenvironment Dec 21, 2021
Propanc Biopharma Enters into $5 Million Equity Purchase Facility with Dutchess Capital Growth Fund LP Dec 14, 2021
Propanc Biopharma Appoints Paul Patrizio as Strategic Advisor to Establish US Based R&D Operating Subsidiary, Cellmed Bio LLC, in New Jersey Nov 3, 2021
Propanc Biopharma Publishes Key Data in Peer Reviewed Journal Confirming Anti-Tumor Potential of Proenzymes May 17, 2021
Professor Juan Marchal Believes Propanc Biopharma’s Proenzyme Therapy May Offer New Treatment Opportunity for Cancer Patients Feb 15, 2021
Propanc Biopharma Appoints Belen Toledo to Evaluate Impact of Proenzyme Therapy on Tumor Microenvironment Jan 28, 2021
Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer Patients Jan 18, 2021
Propanc Biopharma Analyzes Pancreatic Proenzymes Vs T-Cell Therapy Targeting Solid Tumors Such as Pancreatic, Ovarian & Colorectal Cancers Jan 11, 2021
